Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases.
To contact Derek email him directly: derekb.lowe@gmail.com
Twitter: Dereklowe
As if hearing my voice on the page isn't enough, here's a podcast I did last week with Paul Howard of the Manhattan Institute on the FDA's Avastin decision. You might think that they'd be all worked up about this (a la the Wall Street Journal's editorial page), but you might be surprised. . .
1. Anonymous on November 29, 2011 4:36 PM writes...
I like the comment about the false positive results if testing enough subgroups retrospectively and want to read more about this. Can anyone recommend some outstanding reading material for a non-statistician?
1. Anonymous on November 29, 2011 4:36 PM writes...
I like the comment about the false positive results if testing enough subgroups retrospectively and want to read more about this. Can anyone recommend some outstanding reading material for a non-statistician?
Permalink to Comment2. Andy on November 29, 2011 7:22 PM writes...
http://en.wikipedia.org/wiki/Bonferroni_correction
Permalink to Comment3. Dickweed Jones on November 30, 2011 1:11 PM writes...
Both voices sound great.
Permalink to Comment4. SCM on November 30, 2011 5:49 PM writes...
I've been following the avastin debate for a while now, thank you for sharing the podcast!
Permalink to Comment